

Yutaka Seino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2921762/publications.pdf>

Version: 2024-02-01

47
papers

4,312
citations

331259

21
h-index

233125

45
g-index

47
all docs

47
docs citations

47
times ranked

4881
citing authors

#	ARTICLE	IF	CITATIONS
1	Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 2010, 1, 212-228.	1.1	1,206
2	Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine, 2002, 8, 738-742.	15.2	798
3	GIP and GLP-1, the two incretin hormones: Similarities and differences. Journal of Diabetes Investigation, 2010, 1, 8-23.	1.1	467
4	β 2 Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians. Current Diabetes Reports, 2015, 15, 602.	1.7	231
5	Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. Journal of Diabetes Investigation, 2013, 4, 108-130.	1.1	207
6	Expression and role of ionotropic glutamate receptors in pancreatic islet cells. FASEB Journal, 1995, 9, 686-691.	0.2	182
7	Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. Journal of Diabetes Investigation, 2016, 7, 102-109.	1.1	144
8	Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes and Endocrinology, 2020, 8, 377-391.	5.5	104
9	Analysis of factors influencing pancreatic β 2-cell function in Japanese patients with type 2 diabetes: Association with body mass index and duration of diabetic exposure. Diabetes Research and Clinical Practice, 2008, 82, 353-358.	1.1	84
10	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 378-388.	2.2	82
11	Little enhancement of meal-induced glucagon-like peptide-1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. Journal of Diabetes Investigation, 2010, 1, 56-59.	1.1	80
12	Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opinion on Drug Safety, 2015, 14, 795-800.	1.0	73
13	Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. Diabetologia, 2016, 59, 453-461.	2.9	69
14	Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2012, 3, 70-79.	1.1	59
15	Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. Journal of Diabetes and Its Complications, 2015, 29, 413-421.	1.2	53
16	Type 2 diabetes via β 2-cell dysfunction in east Asian people. Lancet Diabetes and Endocrinology, 2016, 4, 2-3.	5.5	52
17	Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial. Journal of Diabetes Investigation, 2016, 7, 565-573.	1.1	50
18	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase III clinical trials. Journal of Diabetes Investigation, 2019, 10, 418-428.	1.1	27

#	ARTICLE	IF	CITATIONS
19	Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β -cell function. Journal of Diabetes Investigation, 2013, 4, 585-594.	1.1	25
20	Lifestyle changes as a result of COVID-19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency. Journal of Diabetes Investigation, 2021, 12, 1718-1722.	1.1	25
21	Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial. Journal of Diabetes Investigation, 2016, 7, 76-84.	1.1	23
22	Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes, Obesity and Metabolism, 2017, 19, 442-447.	2.2	23
23	Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00183.	1.0	23
24	Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 "the gut, the islets or both?. Journal of Diabetes Investigation, 2018, 9, 21-24.	1.1	20
25	Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β -cell function and the achievement of the glycated hemoglobin target 1 year after initiation. Journal of Diabetes Investigation, 2018, 9, 822-830.	1.1	20
26	Glutamate is an essential mediator in glutamine-amplified insulin secretion. Journal of Diabetes Investigation, 2021, 12, 920-930.	1.1	20
27	Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. Journal of Diabetes Investigation, 2019, 10, 902-905.	1.1	18
28	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, Obesity and Metabolism, 2021, 23, 569-580.	2.2	18
29	Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulphonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β -cell function and achievement of HbA1c target one year after initiation. Journal of Diabetes and Its Complications, 2015, 29, 1203-1210.	1.2	17
30	Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. Clinical Medicine Insights: Endocrinology and Diabetes, 2011, 4, CMED.S5976.	1.0	16
31	Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes. Journal of Diabetes Investigation, 2018, 9, 1153-1158.	1.1	14
32	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial. Diabetes, Obesity and Metabolism, 2020, 22, 1062-1073.	2.2	14
33	Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. Journal of Diabetes Investigation, 2021, 12, 2162-2171.	1.1	12
34	Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan. Journal of Diabetes Investigation, 2018, 9, 1203-1211.	1.1	9
35	Cardiovascular safety trials of incretin-based drugs: What do they mean?. Journal of Diabetes Investigation, 2017, 8, 272-276.	1.1	7
36	Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. Journal of Diabetes Investigation, 2022, , .	1.1	7

#	ARTICLE	IF	CITATIONS
37	Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001361.	1.2	6
38	Healthcare resource utilization in patients treated with empagliflozin in East Asia. <i>Journal of Diabetes Investigation</i> , 2022, 13, 810-821.	1.1	6
39	The journey to understanding incretin systems: Theory, practice and more theory. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1171-1173.	1.1	5
40	A novel RFX6 heterozygous mutation (p.R652X) in maturity-onset diabetes mellitus: A case report. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1914-1918.	1.1	5
41	Actual condition survey regarding mismatch of measurements between radioimmunoassay and enzyme-linked immunosorbent assay tests for anti-glutamic acid decarboxylase antibody in real-world clinical practice. <i>Journal of Diabetes Investigation</i> , 2019, 10, 685-689.	1.1	4
42	Solid-phase extraction treatment is required for measurement of active glucagon-like peptide-1 by enzyme-linked immunosorbent assay kit affected by heterophilic antibodies. <i>Journal of Diabetes Investigation</i> , 2019, 10, 302-308.	1.1	3
43	Reply to the comment of Wilbrink <i>et al</i> . on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β -cell function and the achievement of the HbA _{1c} target 1 year after initiation. <i>Journal of Diabetes Investigation</i> , 2018, 9, 981-983.	1.1	2
44	The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1079-1084.	1.1	1
45	A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	1
46	Cover Image, Volume 20, Issue 2. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, i-i.	2.2	0
47	Effects of physician's diabetes self-management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self-monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, open-labeled, prospective randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2021, , .	1.1	0